Sep 15, 2025 01:42PM Wells Fargo Downgrades aTyr Pharma (ATYR) to Equal Weight

Sep 15, 2025 12:55PM Lucid Capital Markets Downgrades aTyr Pharma (ATYR) to Neutral

Sep 15, 2025 12:23PM Jones Trading Downgrades aTyr Pharma (ATYR) to Hold

Sep 15, 2025 11:57AM Leerink Partners Downgrades aTyr Pharma (ATYR) to Market Perform

Sep 15, 2025 11:57AM H.C. Wainwright Downgrades aTyr Pharma (ATYR) to Neutral

Sep 15, 2025 10:58AM Cantor Fitzgerald Downgrades aTyr Pharma (ATYR) to Neutral

Sep 15, 2025 07:26AM aTyr Pharma (ATYR) Halted, News Pending

Sep 12, 2025 06:38AM Cantor Fitzgerald Reiterates Overweight Rating on aTyr Pharma (ATYR)

Aug 22, 2025 05:30AM aTyr Pharma (ATYR) PT Raised to $17 at Jefferies

Aug 4, 2025 06:59AM Cantor Fitzgerald Reiterates Overweight Rating on aTyr Pharma (ATYR)

Jul 29, 2025 10:55AM aTyr Pharma (ATYR) shorted by Shkreli

Jul 23, 2025 06:40AM H.C. Wainwright Reiterates Buy Rating on aTyr Pharma (ATYR)

Jul 22, 2025 03:09PM aTyr Pharma (ATYR) September 3 puts active as share price down 8.2%

Jul 22, 2025 09:07AM aTyr Pharma completes Phase 3 sarcoidosis drug trial enrollment

Jun 26, 2025 08:04AM aTyr Pharma (ATYR) to be Added to the Russell 2000® and Russell 3000 Indexes

Jun 26, 2025 08:00AM Leerink Partners Reiterates Outperform Rating on aTyr Pharma (ATYR)

Jun 5, 2025 06:39AM H.C. Wainwright Reiterates Buy Rating on aTyr Pharma (ATYR)

Jun 4, 2025 08:03AM aTyr Pharma (ATYR) Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease

May 14, 2025 08:02AM aTyr Pharma (ATYR) Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis

May 7, 2025 04:04PM aTyr Pharma, Inc. (ATYR) Tops Q1 EPS by 2c

Apr 23, 2025 09:43AM Cantor Fitzgerald Reiterates Overweight Rating on aTyr Pharma (ATYR)

Apr 21, 2025 06:47AM Cantor Fitzgerald Reiterates Overweight Rating on aTyr Pharma (ATYR)

Mar 26, 2025 08:01AM aTyr Pharma (ATYR) Appoints Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise

Mar 17, 2025 07:06AM Cantor Fitzgerald says 15% of biotech companies down 40% or more

Mar 14, 2025 06:51AM H.C. Wainwright Reiterates Buy Rating on aTyr Pharma (ATYR)

Mar 14, 2025 06:40AM Cantor Fitzgerald Reiterates Overweight Rating on aTyr Pharma (ATYR)

Mar 13, 2025 04:23PM aTyr Pharma, Inc. (ATYR) Tops Q4 EPS by 5c

Mar 12, 2025 04:00PM aTyr Pharma (ATYR) Announces Publication Demonstrating Efzofitimod’s Immunomodulatory Activity in Science Translational Medicine

Mar 6, 2025 04:03PM aTyr Pharma (ATYR) Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT Study

Feb 19, 2025 06:40AM Freedom Broker Starts aTyr Pharma (ATYR) at Buy

Jan 3, 2025 08:23AM Piper Sandler Explores Direct and Indirect Catalysts for Selected Biotechnology Companies

Dec 21, 2024 10:00AM RBC report: Biotech faces both uncertainty and growth opportunities in 2025

Dec 12, 2024 04:01PM aTyr Pharma (ATYR) Appoints Eric Benevich to its Board

Dec 10, 2024 08:01AM aTyr Pharma (ATYR) Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT Study in Pulmonary Sarcoidosis

Nov 19, 2024 08:07AM Lucid Capital Markets Starts aTyr Pharma (ATYR) at Buy

Oct 29, 2024 07:27AM H.C. Wainwright Reiterates Buy Rating on aTyr Pharma (ATYR)

Oct 21, 2024 07:35AM Piper Sandler Reiterates Overweight Rating on aTyr Pharma (ATYR)

Oct 14, 2024 08:00AM aTyr Pharma to Present at the LD Micro Main Event XVII in October

Oct 9, 2024 02:18PM Jones Trading Reiterates Buy Rating on aTyr Pharma (ATYR)

Oct 8, 2024 08:01AM aTyr Pharma's (ATYR) Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting

Oct 4, 2024 06:07AM Wells Fargo Starts aTyr Pharma (ATYR) at Overweight

Oct 2, 2024 08:02AM aTyr Pharma (ATYR) Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal

Sep 7, 2024 08:00PM Here's the list of biotech stocks that have key data catalysts in 2025

Sep 5, 2024 03:15AM Jefferies Starts aTyr Pharma (ATYR) at Buy

Aug 13, 2024 04:20PM aTyr Pharma, Inc. (ATYR) Tops Q2 EPS by 1c